2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.31 (Poster) Impact of Targeted Pathology Education Designed to Address Challenges in Biomarker Testing and Treatment for NSCLC

PP01.31 (Poster) Impact of Targeted Pathology Education Designed to Address Challenges in Biomarker Testing and Treatment for NSCLC

Back to course

Pdf Summary

Advances in precision oncology have led to targeted treatments for non-small cell lung cancer (NSCLC), making biomarker testing essential for diagnosis and treatment. However, keeping up with the rapidly evolving landscape has been a challenge for pathology teams. To address this, a 3-year multimodal CME/CMLE series was created to provide education on biomarkers, sample selection, testing methodologies, and guidelines.<br /><br />The program engaged over 10,000 learners, and 92% of respondents indicated they learned something new. Learners expressed plans to make changes in their practices, such as improving specimen handling, increasing biomarker testing, recommending targeted treatments, utilizing appropriate biomarkers for therapy selection, modifying pathology reports, and improving communication. <br /><br />The programs aimed to expand the use of molecular testing and improve diagnostics and workflows in NSCLC. They also unearthed new educational needs, particularly around treatment response. As the landscape of NSCLC testing and treatment continues to evolve, ongoing education will benefit pathology teams. <br /><br />The study was funded by independent educational grants from Pfizer, Inc.; AstraZeneca; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Asset Subtitle

Melissa Kelly

Keywords

precision oncology

targeted treatments

NSCLC

biomarker testing

education

sample selection

testing methodologies

pathology teams

molecular testing

diagnostics